In contrast, δOR agonists have shown promise in rodent models of chronic pain and generally lack the undesired effects of μOR agonists3, including respiratory depression, addiction liability, or constipation. The gene discussed is OPRM1; the disease is Respiratory insufficiency due to muscle weakness.